Department of Biochemistry, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.
FASEB J. 2019 Jan;33(1):557-571. doi: 10.1096/fj.201800907RR. Epub 2018 Jul 12.
Diffuse gliomas often carry point mutations in isocitrate dehydrogenase ( IDH1), resulting in metabolic stress. Although IDH gliomas are difficult to culture in vitro, they thrive in the brain via diffuse infiltration, suggesting brain-specific tumor-stroma interactions that can compensate for IDH-1 deficits. To elucidate the metabolic adjustments in clinical IDH gliomas that contribute to their malignancy, we applied a recently developed method of targeted quantitative RNA next-generation sequencing to 66 clinical gliomas and relevant orthotopic glioma xenografts, with and without the endogenous IDH-1 mutation. Datasets were analyzed in R using Manhattan plots to calculate distance between expression profiles, Ward's method to perform unsupervised agglomerative clustering, and the Mann Whitney U test and Fisher's exact tests for supervised group analyses. The significance of transcriptome data was investigated by protein analysis, in situ enzymatic activity mapping, and in vivo magnetic resonance spectroscopy of orthotopic IDH1- and IDH-glioma xenografts. Gene set enrichment analyses of clinical IDH1 gliomas strongly suggest a role for catabolism of lactate and the neurotransmitter glutamate, whereas, in IDH gliomas, processing of glucose and glutamine are the predominant metabolic pathways. Further evidence of the differential metabolic activity in these cancers comes from in situ enzymatic mapping studies and preclinical in vivo magnetic resonance spectroscopy imaging. Our data support an evolutionary model in which IDH glioma cells exist in symbiosis with supportive neuronal cells and astrocytes as suppliers of glutamate and lactate, possibly explaining the diffuse nature of these cancers. The dependency on glutamate and lactate opens the way for novel approaches in the treatment of IDH gliomas.-Lenting, K., Khurshed, M., Peeters, T. H., van den Heuvel, C. N. A. M., van Lith, S. A. M., de Bitter, T., Hendriks, W., Span, P. N., Molenaar, R. J., Botman, D., Verrijp, K., Heerschap, A., ter Laan, M., Kusters, B., van Ewijk, A., Huynen, M. A., van Noorden, C. J. F., Leenders, W. P. J. Isocitrate dehydrogenase 1-mutated human gliomas depend on lactate and glutamate to alleviate metabolic stress.
弥漫性神经胶质瘤常携带异柠檬酸脱氢酶(IDH1)点突变,导致代谢应激。尽管 IDH 神经胶质瘤在体外难以培养,但它们通过弥漫性浸润在大脑中茁壮成长,这表明存在大脑特异性的肿瘤-基质相互作用,可以弥补 IDH-1 的缺陷。为了阐明导致 IDH 神经胶质瘤恶性程度的临床 IDH 神经胶质瘤的代谢调整,我们应用最近开发的靶向定量 RNA 下一代测序方法对 66 例临床神经胶质瘤和相关的原位神经胶质瘤异种移植瘤进行了研究,这些肿瘤既有内源性 IDH-1 突变,也没有内源性 IDH-1 突变。使用曼哈顿图在 R 中分析数据集,以计算表达谱之间的距离,使用 Ward 方法进行无监督聚集聚类,使用 Mann Whitney U 检验和 Fisher 精确检验进行有监督的组分析。通过蛋白质分析、原位酶活性映射和 IDH1-和 IDH-神经胶质瘤异种移植瘤的体内磁共振波谱对转录组数据的意义进行了研究。对临床 IDH1 神经胶质瘤的基因集富集分析强烈表明,乳酸和神经递质谷氨酸的分解代谢起着重要作用,而在 IDH 神经胶质瘤中,葡萄糖和谷氨酰胺的代谢是主要的代谢途径。这些癌症中不同代谢活性的进一步证据来自于原位酶映射研究和临床前体内磁共振波谱成像。我们的数据支持一种进化模型,即 IDH 神经胶质瘤细胞与支持性神经元细胞和星形胶质细胞共生,作为谷氨酸和乳酸的提供者,这可能解释了这些癌症的弥漫性特征。对谷氨酸和乳酸的依赖为 IDH 神经胶质瘤的治疗开辟了新的途径。